Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Compare

931 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RARE Analyst Ratings

Strong Buy

16 Buy

1 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Ultragenyx

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$84.07

▲(195.60%Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $84.07 with a high forecast of $136.00 and a low forecast of $35.00. The average price target represents a 195.60% change from the last price of $28.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","82":"$82","137":"$137","54.5":"$54.5","109.5":"$109.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$136.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$84.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,54.5,82,109.5,137],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,36.713846153846156,44.98769230769231,53.261538461538464,61.535384615384615,69.80923076923077,78.08307692307693,86.35692307692308,94.63076923076923,102.90461538461538,111.17846153846153,119.4523076923077,127.72615384615385,{"y":136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,32.71923076923077,36.99846153846154,41.277692307692305,45.55692307692308,49.83615384615385,54.11538461538461,58.394615384615385,62.673846153846156,66.95307692307692,71.23230769230769,75.51153846153846,79.79076923076923,{"y":84.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.944615384615386,29.44923076923077,29.953846153846154,30.45846153846154,30.963076923076922,31.467692307692307,31.972307692307695,32.47692307692308,32.98153846153846,33.48615384615385,33.99076923076923,34.495384615384616,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$136.00

Average Price Target$84.07

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$27

Hold

-5.06%

Downside

Reiterated

08/01/25

Ultragenyx Pharmaceutical faces significant financial challenges, including profitability and cash flow issues, which heavily impact the stock score. Technical indicators suggest bearish momentum, further weighing on the score. Although the earnings call provided optimistic guidance and the company has notable clinical advancements, these positives are currently overshadowed by financial and technical weaknesses.

Allison BratzelPiper Sandler

Piper Sandler

$105

Buy

269.20%

Upside

Reiterated

07/28/25

Piper Sandler Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$80

Buy

181.29%

Upside

Initiated

07/28/25

Ultragenyx assumed with a Buy at H.C. WainwrightUltragenyx assumed with a Buy at H.C. Wainwright

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

07/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Intuitive Surgical (NASDAQ: ISRG), Quest Diagnostics (NYSE: DGX) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Tazeen AhmadBank of America Securities

Bank of America Securities

$80→$79

Buy

177.78%

Upside

Reiterated

07/15/25

Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval

Yaron WerberTD Cowen

TD Cowen

$86

Buy

202.39%

Upside

Reiterated

07/14/25

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

07/14/25

Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data

Maxwell SkorMorgan Stanley

Morgan Stanley

$65→$55

Buy

93.39%

Upside

Reiterated

07/13/25

Ultragenyx price target lowered to $55 from $65 at Morgan StanleyUltragenyx price target lowered to $55 from $65 at Morgan Stanley

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/11/25

Ultragenyx's UX111 CRL Not a Major Setback; Focus Remains on Promising Programs with Outperform Rating Maintained

Luca IssiRBC Capital

RBC Capital

$77

Buy

170.75%

Upside

Reiterated

07/11/25

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Roche Holding AG (Other OTC: RHHVF)

Liisa BaykoEvercore ISI

Evercore ISI

$70

Buy

146.13%

Upside

Reiterated

07/10/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Salveen RichterGoldman Sachs

Goldman Sachs

$82

Buy

188.33%

Upside

Reiterated

07/10/25

Goldman Sachs Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Laura ChicoWedbush

Wedbush

$39→$35

Hold

23.07%

Upside

Reiterated

07/10/25

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Whitney IjemCanaccord Genuity

Canaccord Genuity

$136

Buy

378.20%

Upside

Assigned

07/09/25

Ultragenyx Pharmaceutical: A Compelling Buy Amid Market Overreaction and Growth Prospects

Yigal NochomovitzCiti

Citi

$110

Buy

286.78%

Upside

Reiterated

07/09/25

Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid ORBIT Trial Optimism and Undervalued Stock Price

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$27

Hold

-5.06%

Downside

Reiterated

08/01/25

Allison BratzelPiper Sandler

Piper Sandler

$105

Buy

269.20%

Upside

Reiterated

07/28/25

Piper Sandler Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

Ram SelvarajuH.C. Wainwright

H.C. Wainwright

$80

Buy

181.29%

Upside

Initiated

07/28/25

Ultragenyx assumed with a Buy at H.C. WainwrightUltragenyx assumed with a Buy at H.C. Wainwright

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

07/23/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Intuitive Surgical (NASDAQ: ISRG), Quest Diagnostics (NYSE: DGX) and Ultragenyx Pharmaceutical (NASDAQ: RARE)

Tazeen AhmadBank of America Securities

Bank of America Securities

$80→$79

Buy

177.78%

Upside

Reiterated

07/15/25

Positive Outlook on Ultragenyx Pharmaceutical Despite Setback with UX111 Approval

Yaron WerberTD Cowen

TD Cowen

$86

Buy

202.39%

Upside

Reiterated

07/14/25

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

07/14/25

Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data

Maxwell SkorMorgan Stanley

Morgan Stanley

$65→$55

Buy

93.39%

Upside

Reiterated

07/13/25

Ultragenyx price target lowered to $55 from $65 at Morgan StanleyUltragenyx price target lowered to $55 from $65 at Morgan Stanley

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

07/11/25

Ultragenyx's UX111 CRL Not a Major Setback; Focus Remains on Promising Programs with Outperform Rating Maintained

Luca IssiRBC Capital

RBC Capital

$77

Buy

170.75%

Upside

Reiterated

07/11/25

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Roche Holding AG (Other OTC: RHHVF)

Liisa BaykoEvercore ISI

Evercore ISI

$70

Buy

146.13%

Upside

Reiterated

07/10/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Salveen RichterGoldman Sachs

Goldman Sachs

$82

Buy

188.33%

Upside

Reiterated

07/10/25

Goldman Sachs Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Laura ChicoWedbush

Wedbush

$39→$35

Hold

23.07%

Upside

Reiterated

07/10/25

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Whitney IjemCanaccord Genuity

Canaccord Genuity

$136

Buy

378.20%

Upside

Assigned

07/09/25

Ultragenyx Pharmaceutical: A Compelling Buy Amid Market Overreaction and Growth Prospects

Yigal NochomovitzCiti

Citi

$110

Buy

286.78%

Upside

Reiterated

07/09/25

Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid ORBIT Trial Optimism and Undervalued Stock Price

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

1 Month

xxx

Success Rate

12/19 ratings generated profit

Average Return

+4.22%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.16% of your transactions generating a profit, with an average return of +4.22% per trade.

3 Months

xxx

Success Rate

10/19 ratings generated profit

Average Return

+1.08%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +1.08% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

7/19 ratings generated profit

Average Return

+2.33%

reiterated a buy rating 12 days ago

Copying Joon Lee's trades and holding each position for 1 Year would result in 36.84% of your transactions generating a profit, with an average return of +2.33% per trade.

2 Years

xxx

Success Rate

10/28 ratings generated profit

Average Return

+4.35%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.71% of your transactions generating a profit, with an average return of +4.35% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RARE has received 24 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 84.07.

Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$1.30 with a range of -$1.45 to -$1.04. The previous quarter’s EPS was -$1.57. RARE beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.12% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $162.01M with a range of $155.59M to $170.30M. The previous quarter’s sales results were $139.29M. RARE beat its sales estimates 66.67% of the time in past 12 months, while its overall industry beat sales estimates 47.05% of the time in the same period. In the last calendar year RARE has Outperformed its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?

Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 84.07.

What is RARE’s upside potential, based on the analysts’ average price target?

Ultragenyx Pharmaceutical has 195.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RARE a Buy, Sell or Hold?

Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ultragenyx Pharmaceutical’s price target?

The average price target for Ultragenyx Pharmaceutical is 84.07. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $136.00 ,the lowest forecast is $35.00. The average price target represents 195.60% Increase from the current price of $28.44.

What do analysts say about Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of RARE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

RARE Analyst Ratings

RARE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ultragenyx Pharmaceutical

RARE Analyst Recommendation Trends

RARE Financial Forecast

RARE Earnings Forecast

RARE Sales Forecast

RARE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts